CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GSK plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GSK plc
980 Great West Road
Phone: +44 2080475000p:+44 2080475000 BRENTFORD, TW8 9GS  United Kingdom Ticker: GSKGSK
Business Summary
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes the lead molecule IDRX-42, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve patients with gastrointestinal stromal tumors (GIST).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Jonathan R.Symonds 65 9/1/2019 9/1/2019
Chief Executive Officer, Executive Director Emma N.Walmsley 55 4/1/2017 10/1/2011
Chief Financial Officer, Executive Director JulieBrown 62 5/1/2023 4/3/2023
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
GLAXO SMITHKLINE PHILS. INC. INES
GSK Capital B.V. Netherlands
GSK Consumer Healthcare Holdings (No.2) Limited United Kingdom
39 additional Subsidiary records available in full report.

Business Names
Business Name
1506369 Alberta ULC
Action Potential Venture Capital Limited
Adechsa GmbH
438 additional Business Names available in full report.

General Information
Number of Employees: 68,629 (As of 12/31/2024)
Outstanding Shares: 4,117,853,751 (As of 4/14/2025)
Shareholders: 58,027
Stock Exchange: LON
Federal Tax Id: 000005710
Fax Number: +44 2080477807


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 16, 2025